{"id":395437,"date":"2020-12-08T09:03:59","date_gmt":"2020-12-08T14:03:59","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=395437"},"modified":"2020-12-08T09:03:59","modified_gmt":"2020-12-08T14:03:59","slug":"seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/","title":{"rendered":"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Dec. 8, 2020<\/span> \/PRNewswire\/ —\u00a0Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 10th<\/sup> Annual LifeSci Partners Corporate Access Event, January 6-8<\/span> and 11-14, 2021. <\/p>\n

\n

\n
\n \"(PRNewsfoto\/Seelos
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Raj Mehra, Ph.D., Chairman and CEO, will host 1×1 meetings via conference calls. <\/p>\n

For additional information about the 10th<\/sup> Annual LifeSci Partners Corporate Access Event: https:\/\/www.lifesciadvisors.com\/<\/a><\/p>\n

\n About Seelos Therapeutics<\/b>\n <\/p>\n

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson’s Disease, other psychiatric and movement disorders plus orphan diseases.<\/p>\n

For more information, please visit our website: http:\/\/seelostherapeutics.com<\/a>, the content of which is not incorporated herein by reference.<\/p>\n

Contact Information:<\/p>\n

\n Anthony Marciano<\/span>
\n
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY<\/span> 10022
(646) 293-2136
anthony.marciano@seelostx.com<\/a>
https:\/\/seelostherapeutics.com\/<\/a>
https:\/\/twitter.com\/seelostx<\/a>
https:\/\/www.linkedin.com\/company\/seelos<\/a>\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event-301187641.html<\/a><\/p>\n

SOURCE Seelos Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Dec. 8, 2020 \/PRNewswire\/ —\u00a0Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021. Raj Mehra, Ph.D., Chairman and CEO, will host 1×1 meetings via conference calls. For additional information about the 10th Annual LifeSci Partners Corporate Access Event: https:\/\/www.lifesciadvisors.com\/ About Seelos Therapeutics Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust … <\/p>\n

Continue reading “Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-395437","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSeelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Dec. 8, 2020 \/PRNewswire\/ —\u00a0Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021. Raj Mehra, Ph.D., Chairman and CEO, will host 1×1 meetings via conference calls. For additional information about the 10th Annual LifeSci Partners Corporate Access Event: https:\/\/www.lifesciadvisors.com\/ About Seelos Therapeutics Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust … Continue reading "Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-08T14:03:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event\",\"datePublished\":\"2020-12-08T14:03:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/\"},\"wordCount\":251,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/\",\"name\":\"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\",\"datePublished\":\"2020-12-08T14:03:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/","og_locale":"en_US","og_type":"article","og_title":"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event - Market Newsdesk","og_description":"PR Newswire NEW YORK, Dec. 8, 2020 \/PRNewswire\/ —\u00a0Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021. Raj Mehra, Ph.D., Chairman and CEO, will host 1×1 meetings via conference calls. For additional information about the 10th Annual LifeSci Partners Corporate Access Event: https:\/\/www.lifesciadvisors.com\/ About Seelos Therapeutics Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust … Continue reading \"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-08T14:03:59+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event","datePublished":"2020-12-08T14:03:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/"},"wordCount":251,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/","name":"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","datePublished":"2020-12-08T14:03:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=395437"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/395437\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=395437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=395437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=395437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}